Journal of Clinical and Experimental Hematopathology
Online ISSN : 1880-9952
Print ISSN : 1346-4280
ISSN-L : 1346-4280
Original Article
Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines
Chaoya MaHasita HorladCheng PanHiromu YanoKoji OhnishiYukio FujiwaraMasao MatsuokaAeju LeeTakuro NiidomeRyuya YamanakaMotohiro TakeyaYoshihiro Komohara
Author information
Keywords: PD-L1, PD-L2, Stat3, lymphoma

2017 Volume 57 Issue 1 Pages 21-25


Recent studies have indicated the significance of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domain-containing molecule-3 for anti-tumor immune responses. We previously investigated PD-1 ligand 1/2 (PD-L1/2) expression in lymphoma cell lines, and found that PD-L1/2 is expressed on the adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines. In the present study, we investigated whether the Stat3 inhibitor WP1066 abrogated PD-L1/2 expression in lymphoma cell lines. Incubation with WP1066 inhibited lymphoma cell growth and induced cell apoptosis. PD-L1/2 expression in the ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines was significantly abrogated by WP1066 treatment. These data indicated that a Stat3 inhibitor abrogated PD-L1/2 expression in lymphoma cells. Such an inhibitor is therefore considered to be useful for additional immunotherapy in patients with advanced lymphoma.

Information related to the author
© 2017 by The Japanese Society for Lymphoreticular Tissue Research
Previous article Next article